Recruiting
Phase 1

LY4167586

Sponsor:

Eli Lilly and Company

Code:

NCT07881887

Conditions

Obesity

Overweight

Diabetes Mellitus, Type 2

Eligibility Criteria

Sex: All

Age: 18 - 65

Healthy Volunteers: Not accepted

Interventions

LY4167586

Placebo

Study Details

Brief summary:

The main purpose of this study is to look at how safe and well-tolerated LY4167586 is in participants with obesity or overweight with or without Type 2 Diabetes. Blood tests will be performed to check how much LY4167586 gets into the bloodstream and how long it takes the body to eliminate it following a single administration.

Participation in the study will last between approximately 53 to 89 weeks. For each participant (excluding those in Part B), the study will include between 5 and 7 stays in the Clinical Research Unit (CRU), each stay lasting between approximately 8 and 10 nights.

Conditions

Obesity

Overweight

Diabetes Mellitus, Type 2

Study ID

NCT07881887

Start date

Oct 22, 2026

Status verified date

Nov, 2026

Completion date

Mar, 2029

Anticipated

Primary completion date

Mar, 2029

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18 - 65

Healthy Volunteers: Not accepted

Inclusion Criteria:

  • Participants must be 21 in Singapore.
  • Have had a self-reported stable weight for 3 months prior to screening (less than approximately 5 percent (%) body weight change.

Part A, B, D, and E

  • Have a body mass index (BMI) of greater than or equal to 30 kilograms per square meter (kg/m²) or 27 to less than 30 kg/m² and previously diagnosed with at least one of the following weight-related comorbidities:

  • hypertension
  • dyslipidemia
  • obstructive sleep apnea, or
  • prediabetes.

Part C

  • Have a BMI ≥25.0 kg/m²
  • Have a diagnosis of Type 2 Diabetes (T2D) for at least 6 months.
  • T2D controlled with diet and exercise alone or are on a stable dose of metformin alone, or in combination with a sodium-glucose co-transporter-2 inhibitor (SGLT-2i), for at least 3 months.
  • Have a hemoglobin (HbA1c) value of ≥6.5 % and ≤10.0%.

Part D

  • To qualify as Chinese for this study, the participant must be at a minimum third-generation Chinese, defined as having all 4 of the participants' biological grandparents being of exclusive Chinese descent and born in China.

Part E

  • To qualify as Japanese for this study, the participant must be at a minimum third-generation Japanese, defined as having all 4 of the participants' biological grandparents being of exclusive Japanese descent and born in Japan.

Exclusion Criteria:

  • Have a significant history or presence of cardiovascular, respiratory, hepatic, renal, gastrointestinal (GI), endocrine (except for T2D in Part C), hematological, or neurological disorders capable of significantly altering the absorption, metabolism, or elimination of drugs, or of constituting a risk when taking the study drug, or of interfering with the interpretation of data.

Study Design

Enrollment

617 participants

Anticipated

Allocation

Randomized

Intervention Model

Parallel Assignment

Primary purpose

Treatment

Interventions and Outcome Measures

Arms

experimental: Part A: LY4167586

LY4167586 administered subcutaneously (SC)

experimental: Part B LY4167586

LY4167586 administered SC

experimental: Part C LY4167586

LY4167586 administered SC

experimental: Part D LY4167586

LY4167586 administered SC

experimental: Part E LY4167586

LY4167586 administered SC

placebo comparator: Placebo (Part A-E)

Placebo administered SC

Interventions

LY4167586

administered SC

Placebo

administered SC

Primary outcome measure

  • Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration [ Time Frame: Baseline through Study Completion (Estimated as Week 89) ]

Central Contacts and Locations

Central contacts

Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or

1-317-615-4559LillyTrials@Lilly.com

Physicians interested in becoming principal investigators please contact

clinical_inquiry_hub@lilly.com

Locations

CenExel ACT

Recruiting

Anaheim, California, United States, 92801

Principal Investigator:

Amina Haggag

Collaborative Neuroscience Network - CNS

Recruiting

Los Alamitos, California, United States, 90720

Principal Investigator:

Steven Reynolds

Diablo Clinical Research, Inc.

Recruiting

Walnut Creek, California, United States, 94598

Principal Investigator:

Bonnie Kimmel

Fortrea Clinical Research Unit

Recruiting

Daytona Beach, Florida, United States, 32117

Contacts

Principal Investigator:

Chiamaka Iheme

Clinical Site Partners, LLC DBA CSP Orlando

Recruiting

Winter Park, Florida, United States, 32789

Principal Investigator:

ROBERT MEYER

Centricity Research

Recruiting

Columbus, Georgia, United States, 31904

Contacts

Principal Investigator:

Joseph Surber

CenExel iResearch, LLC

Recruiting

Decatur, Georgia, United States, 30030

Principal Investigator:

Kimball Johnson

QPS

Recruiting

Springfield, Missouri, United States, 65802

Contacts

Principal Investigator:

Leea Reed

CenExel-HRI

Recruiting

Marlton, New Jersey, United States, 08053

Principal Investigator:

Kyle Coupe

Ohio Clinical Trials

Recruiting

Columbus, Ohio, United States, 43212

Principal Investigator:

Angela Eakin

Fortrea Clinical Research Unit

Recruiting

Dallas, Texas, United States, 75247

Principal Investigator:

Archie Bowie

Worldwide Clinical Trials, Inc.

Recruiting

San Antonio, Texas, United States, 78217

Principal Investigator:

Alan Hand

More Information

Sponsor

Eli Lilly and Company

Last update posted

Nov 18, 2026

Last verified

Nov, 2026

Trial information was received from ClinicalTrials.gov and was last updated on 2026-11-19. This information was provided to ClinicalTrials.gov by Eli Lilly and Company on 2026-11-18. Recruitment status is synced daily from ClinicalTrials.gov and may not reflect the sponsor's current status. Confirm during your call.